2De Clercq E. Human viral diseases : what is next for antiviral drugdiscovery? [J]. Curr Opin Virol, 2012,2 (5) : 572-579.
3Bresse X,Annemans L,Pr^aud E, et al. Vaccination against her-peszosterand postherpetic neuralgia in France : a cost-effectivenessanalysis[ J] . Expert Rev Pharmacoecon Outcomes Res, 2013,13(3): 393406.
4Kol§ek M. TENS - an alternative to antiviraldrugs for acute herpeszoster treatment and postherpetic neuralgia prevention [ J] . SwissMed Wkly, 2012’ 141 ; 13229.
5van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the po-tential effects and cost-effectiveness of programmatic herpeszoster-vaccination of elderly in the Netherlands [ J] . BMC Health ServRes, 2010,10: 237.
6Tyring SK, Beutner KR, Tucker BA. et al. Antiviral therapy forherpeszoster : randomized, controlled clinical trial of valacyclovi-rand famciclovir therapy in immunocompetent patients 50 years andolder[J]. Arch Fam Med, 2000,9(9) : 863-869.
